• 1. Department of Medical Statistics, Jinling Hospital, Southern Medical University, Nanjing, 210002, P.R.China;
  • 2. Medical Imaging Center, Jingling Hospital, Nanjing, 210002, P.R.China;
  • 3. Department of Medical Statistics, Jinling Hospital, Nanjing Medical University, Nanjing, 210002, P.R.China;
  • 4. Information Department, Jinling Hospital, Nanjing, 210002, P.R.China;
LIU Yuxiu, Email: liu_yuxiu@163.com
Export PDF Favorites Scan Get Citation

Objectives  To evaluate the reporting quality of Bland-Altman method consistency evaluation in China from 2014 to 2016. Methods  WanFang Data, VIP and CNKI databases were electronically searched to collect literature about the application of Bland-Altman method from 2014 to 2016 in China. Two reviewers screened literature, extracted data, and the data were then statistically analyzed by SPSS 22.0 software. Results  A total of 376 articles were included. The published articles on Bland-Altman method had major flaws (not conforming to reporting standards) in the application conditions, evaluation indexes, graphic depiction and so on. Merely 11.4% of the literature set the clinically acceptable consensus values in the pre-period studies. Merely one literature (0.3%) correctly compared the 95%CI of 95%LoA with the clinically acceptable threshold which had been set previously. The offer rates of the differences between the two measurements and the 95%CI, 95%LoA and 95%CI of 95%LoA in the figure were 95.9%, 9.5%, 94.6% and 4.4%, respectively. Conclusions  The reporting quality of Bland-Altman method consistency evaluation in China is of low quality, specifically not conforming to reporting standards. We should strengthen the introduction of Bland-Altman methodology to improve the reporting quality.

Citation: LIU Tiantian, ZHONG Weihua, LU Mengjie, CHEN Yu, ZHOU Chongchong, WEN Hao, LIU Yuxiu. Reporting quality assessment of Bland-Altman method consistency evaluation in China from 2014 to 2016. Chinese Journal of Evidence-Based Medicine, 2018, 18(1): 67-73. doi: 10.7507/1672-2531.201709019 Copy

  • Previous Article

    Efficacy and safety of Yangzhengxiaoji capsule combined with chemotherapy for malignant digestive tract tumor: a meta-analysis
  • Next Article

    Quality assessment of clinical practice guidelines for benign prostatic hyperplasia